Poseida Therapeutics Inc. announced that Debra Gessner has joined the company as vice president, regulatory affairs. Ms. Gessner brings deep expertise in drug development, regulatory communications and strategy including significant experience in gene therapy and immuno-oncology programs and in working with the FDA’s Office of Cellular, Tissue and Gene Therapies. Ms. Gessner has more than 25 years of hands-on experience in regulatory affairs and compliance. She has served as vice president of regulatory and quality assurance at Tocagen Inc. Gessner is a member of the Regulatory Affairs Professional Society (RAPS), Parental Drug Association (PDA) and American Society for Gene Therapy, among others, and she plays an active role in the University of California, Los Angeles Technology Development Group Entrepreneurs-in-Residence Program.